

Long noncoding RNA LUCAT1 promotes cervical cancer cell proliferation and invasion by upregulating MTA1

A.-H. WANG¹, J.-M. ZHAO¹, J. DU¹, Q.-X. PANG¹, M.-O. WANG²

¹Yan'an Key Laboratory of Cancer Prevention and Treatment, School of Medicine, Yan'an University, Yan'an, China

²Department of Interventional Radiology, Affiliated Hospital of Yan'an University, Yan'an, China

Aihong Wang and Jumei Zhao contributed equally to this work

Abstract. – **OBJECTIVE:** Recent researches have revealed the role of long noncoding RNAs (lncRNAs) in the development of tumors. In this study, lncRNA LUCAT1 was explored to identify how it affected the progression of cervical cancer.

PATIENTS AND METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect LUCAT1 expression in both cervical cancer cells and tissue samples. Moreover, the associations between LUCAT1 expression level and patients' overall survival time were explored, respectively. Cell proliferation assay and transwell assay were conducted. Furthermore, the underlying mechanism was explored via protein expression of MTA1 and Western blot assay.

RESULTS: By comparing with the expression level in corresponding ones, the LUCAT1 expression level in cervical cancer tissues was significantly higher. Moreover, expression level of LUCAT1 was negatively correlated with patients' overall survival time. In addition, after LUCAT1 was overexpressed, cell proliferation, cell invasion and migration capacities were promoted *in vitro*. In addition, the mRNA and protein expressions of MTA1 were upregulated after LUCAT1 was overexpressed. Furthermore, it was found that the expression level of MTA1 was positively related to LUCAT1 expression level in cervical cancer tissues.

CONCLUSIONS: We showed that LUCAT1 could promote proliferation, invasion and migration of cervical cancer cells through upregulating MTA1, which might offer a potential therapeutic choice for patients with cervical cancer.

Key Words:

Long noncoding RNA, LUCAT1, MTA1, Cervical cancer.

Introduction

Cervical cancer is the fourth most common malignancy in female all over the world and the most prevalent cancer among Chinese women. IARC [1] has indicated that more than half a million cases were newly diagnosed as breast cancer in 2012, which accounts for 7.5% of female cancer-related deaths¹. Basic treatments for patients with cervical cancer include surgery or a concurrent chemoradiotherapy, which consists of cisplatin-based chemotherapy and radiotherapy. The prognosis of patients with metastatic cervical cancer is very poor. In many developing countries, due to the grossly deficient treatments, cervical cancer kills more than 250,000 women annually². Therefore, it is urgent to find out the underlying mechanism and figure out a new treatment strategy for these unfortunate women. Most of genome transcripts are non-coding RNAs. Long non-coding RNAs (lncRNAs) are one subtype of non-coding RNAs, which are longer than 200 nucleotides in length. In recent years, lncRNAs are widely studied in a variety of biological behaviors. Moreover, evidences have proved that lncRNAs act as a vital role in the progression of malignant tumors. For example, lncRNA PlncRNA-1 acts as an oncogene in the progression of colorectal cancer cell through regulating PI3K/Akt Signaling Pathway³. lncRNA SNHG1 could inhibit the differentiation of Treg cells, thereby impeding the immune escape of breast cancer⁴. lncRNA p23154 accelerates metastasis⁵ in oral squamous cell carcinoma by taking part in glycolysis mediated by Glut1. Moreover, overexpression

of lncRNA CCAT2 has been proved to promote the proliferation and metastasis in intrahepatic cholangiocarcinoma⁶. However, the role of lncRNA LUCAT1 plays in cervical cancer and the underlying molecular mechanism of how it works remains unexplored. In our study, we found out that LUCAT1 expression level was remarkably higher in cervical cancer tissues. Moreover, LUCAT1 promoted the proliferation, invasion and migration capacities of cervical cancer cell *in vitro*. In addition, our further experiment explored the underlying mechanism of how LUCAT1 functioned in the development of cervical cancer.

Patients and Methods

Cell Lines and Clinical Samples

A total of 62 cases that were diagnosed as cervical cancer patients were enrolled in this research. Every patient received surgery at Affiliated Hospital of Yan'an University. Before the surgery, all the written informed consents were gathered. No radiotherapy or chemotherapy for any patients before the operation. Tissues were collected from the surgery and stored immediately at -80°C. All tissues were analyzed by two experienced pathologists. The Research Ethics Committee of Affiliated Hospital of Yan'an University granted the approval for this study.

Cell Culture

SiHa, HeLa, Caski, C33A and C4-1 cervical cancer cell lines, a normal cervical epithelial cell (NC104) and 293T cell (Chinese Type Culture Collection, Chinese Academy of Sciences, Shanghai, China) were used in this study. Culture medium was consisted of penicillin, Dulbecco's Modified Eagle Medium (DMEM, HyClone, South Logan, UT, USA) and 10% fetal bovine serum (FBS; Gibco, Rockville, MD, USA). Besides, cells were cultured in humidified incubator, which contained 5% CO₂ and was set at 37°C.

Transfection

After synthesized, lentiviral virus targeting LUCAT1 was cloned into the pLenti-EF1a-EGFP-E1 vector (Biossetia Inc., San Diego, CA, USA). LUCAT1 lentiviruses (LUCAT1) and the empty vector (control) packaged in 293T cells were then used for transfection in cervical cancer cells. 48 h later, detection of LUCAT1 expression level in these cells was conducted using quantitative Real-time polymerase chain reaction (qRT-PCR).

RNA Extraction and qRT-PCR

The total RNA was separated by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). And then, the total RNA was reverse-transcribed into complementary deoxyribose nucleic acids (cDNAs) through reverse Transcription (TaKaRa Biotechnology Co., Ltd., Dalian, China). Following are the primers using for RT-qPCR: LUCAT1, forward 5'-CCTATCCCTTTCCTAAAG-3' and reverse 5'-ACTTCTGCCGAAACGTC-3'; MTA1, forward 5'-TAGGGACTCAGATGAGATGGCCGCCAATGTAG-3' and reverse 5'-GATCCCGGCGCGGTATCGTGCTCCTCGATGAGATGATC-3'; GAPDH, forward 5'-AAAATCAAGGCGCAATGCTGG-3' and reverse 5'-GGGCATGACTGTGTCAAGAA-3'. The thermal cycle was as follows: 30 s at 95°C, 5 s at 95°C for 40 cycles and 1 min at 60°C.

Western Blot Analysis

Reagent rabbit immunoprecipitation assay (RIPA) (Beyotime, Shanghai, China) was utilized to extract protein from cells. Bicinchoninic acid (Bioassay, Protein assay kit (TaKaRa, Dalian, China) was chosen for quantifying protein concentration. The target proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Next, they were incubated with antibodies after replaced to the polyvinylidene difluoride (PVDF) membrane (Roche, Basel, Switzerland). Cell Signaling Technology (CST, Danvers, MA, USA) provided us with rabbit anti-GAPDH and rabbit anti-MTA1, as well as goat anti-rabbit secondary antibody. Chemiluminescent film was applied for assessment of protein expression with Image J software.

Colony Formation Assay

After cultured with fetal bovine serum (FBS) in a 6-well plate for 14 days, all cells were fixed with methanol and stained with 0.1% crystal violet. Meanwhile, we counted number of colonies for comparison.

Cell Counting Kit-8 (CCK8) Assay

Cell growth of these treated cells in 96-well plates was monitored every 24 h by CCK8 assay by following the protocol (Dojindo Molecular Technologies, Inc.). The absorbance was examined at 450 nm via Spectrophotometer (Thermo Scientific, Waltham, MA, USA).




Figure 1. Expression levels of LUCAT1 were increased in cervical cancer tissues and cell lines, which was associated with poorer overall survival of cervical cancer patients. **A**, LUCAT1 expression was significantly increased in cervical cancer tissues compared with adjacent tissues. **B**, Expression levels of LUCAT1 relative to GAPDH were detected in the human cervical cancer cell lines and NC104 (normal cervical epithelium cell line) by qRT-PCR. **C**, High level of LUCAT1 was associated with poorer overall survival of cervical cancer patients. Data are presented as the mean \pm standard error of the mean, $p < 0.05$.

Matrigel Assay

5×10^4 cells in 200 μ L of serum-free DMEM were transformed to top chamber of an 8 μ m pore size insert (Millipore, Billerica, MA, USA) coated with or without 50 μ g Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). And the bottom chamber was added with Dulbecco's Modified Eagle's Medium (DMEM) and fetal bovine serum (FBS). 48 h later, after wiped by cotton swab, the top surface of chambers was immersed for 1 min with precooling methanol and stained in crystal violet for 30 min. Three fields were selected to count the data for invasion membrane.

Statistical Analysis

Statistical Product and Service Solutions (SPSS) 20.0 (IBM, Armonk, NY, USA) was utilized to conduct statistical analysis. Data were presented as mean \pm SD. Student *t*-test, χ^2 -test and Kaplan-Meier method were performed when appropriate. When $p < 0.05$, it was considered statistically significant.

Results

Overexpression of LUCAT1 in Cervical Cancer Tissues and Cells

Firstly, the expression of LUCAT1 was detected by performing qRT-PCR in 62 patients' samples and 4 cervical cancer cell lines. The results revealed that LUCAT1 was significantly up-regulated in tumor tissue samples (Figure 1A). Expression level of LUCAT1 in cervical cancer cells was remarkably higher than that of NC104 (normal cervical epithelium cell line) (Figure 1B).

LUCAT1 Expression Correlated With Overall Survival Time of Cervical Cancer Patients

Kaplan-Meier method was utilized to analyze patients' survival time after the surgery. By median expression of cervical cancer patients were randomly divided into two groups, the low-LUCAT1 group and high-LUCAT1 group. The results of Kaplan-Meier analysis showed that cervical cancer patients had a better overall survival with lower LUCAT1 level (Figure 1C).

Overexpression of LUCAT1 Promoted Cell Proliferation in Cervical Cancer

HeLa cervical cancer cell line was used for the overexpression of LUCAT1 in this study. The LUCAT1 expression was detected by qRT-PCR (Figure 2A). Then outcome of colony formation assay revealed that overexpression of LUCAT1 promoted ovarian cancer cell growth (Figure 2B). Moreover, results of cell proliferation assay indicated that the growth ability of cervical cancer cells was significantly facilitated after LUCAT1 was overexpressed (Figure 2C).

Overexpression of LUCAT1 Enhanced Migration and Invasion in Cervical Cancer Cells

The outcome of wound healing assay revealed that after LUCAT1 was overexpressed, the migration ability of cervical cancer cells was promoted (Figure 3A). Furthermore, the results of transwell assay also revealed that the quantity of migrant and invaded cells was remarkably increased after LUCAT1 was overexpressed in cervical cancer cells (Figure 3B and 3C).




Figure 2. Overexpression of LUCAT1 promoted cervical cancer cell proliferation. **A**, LUCAT1 expression in cervical cancer cells transduced with LUCAT1 lentiviruses (LUCAT1) and the empty vector (control) was detected by qRT-PCR. GAPDH was used as an internal control. **B**, Colony formation assay showed that number of colonies in LUCAT1 lentivirus group was significantly increased compared with empty control group in cervical cancer cells. **C**, Cell proliferation assay showed that overexpression of LUCAT1 significantly increased cell growth in cervical cancer cells. The results represent the average of three independent experiments (mean \pm standard error of the mean). * $p < 0.05$, as compared with the control cells.

The Interaction Between MTA1 and LUCAT1 in Cervical Cancer

The results of qRT-PCR showed that the expression level of MTA1 was significantly higher in LUCAT1 lentiviruses (LUCAT1) group when compared with that in empty vector (control) group (Figure 4A). The outcome of Western blot assay revealed that after LUCAT1 was overexpressed, MTA1 could be upregulated at protein level (Figure 4B). Furthermore, we found that MTA1 expression in cervical cancer tissues was significantly higher when compared with that of adjacent tissues (Figure 4C). Correlation analysis demonstrated that MTA1 expression level positively correlated to LUCAT1 expression in cancer tissues (Figure 4D).

in the development of cervical cancer. For example, overexpression of lncRNA ZNF667-AS1 represses the progression of cervical cancer, which is also related to the prognosis of cervical cancer⁷. Overexpression of lncRNA PANDAR promotes the growth of cervical cancer cells and predicts the poor prognosis of patients with cervical cancer⁸. LncRNA ERNDE enhances the proliferation and metastasis of cervical cancer cells⁹. Through regulation of miR-21-5p, lncRNA MEG3 acts as a tumor suppressor in cervical cancer, leading to the inhibition of tumor growth¹⁰.

Lung cancer associated transcript 1 (LUCAT1) is a long noncoding RNA located on chromosome 5, which was found in the airway epithelium of cigarette smokers firstly¹¹. Recently, lncRNA is widely explored for its important role in the development of tumors. For instance, overexpression of lncRNA LUCAT1 could promote cell proliferation in human non-small lung cancer through inhibiting the expression of p21 and p57¹². LncRNA LUCAT1 inhibits

Discussion

LncRNAs have been proved to be associated with pathogenesis of many cancers. Evidence revealed that lncRNAs function as a crucial part




Figure 3. Overexpression of LUCAT1 promoted cervical cancer cell migration and invasion. **A**, Wound-healing assay showed that migrated length of cervical cancer cells was significantly increased via overexpression of LUCAT1 in cervical cancer cells. **B**, Transwell assay showed that number of migrating cells was significantly increased via overexpression of LUCAT1 in cervical cancer cells (magnification, 40 \times). **C**, Transwell assay showed that number of invading cells was significantly increased via overexpression of LUCAT1 in cervical cancer cells (magnification, 40 \times). The results represent the average of three independent experiments (mean \pm standard error of the mean). * $p < 0.05$, as compared with the control cells.




Figure 4. Interaction between LUCAT1 and MTA1. **A**, RT-PCR results showed that MTA1 expression was higher in LUCAT1 lentiviruses (LUCAT1) compared with the empty vector (control). **B**, Western blot assay revealed that MTA1 protein expression was increased in LUCAT1 lentiviruses (LUCAT1) compared with the empty vector (control). **C**, MTA1 was significantly upregulated in cervical cancer tissues compared with adjacent tissues. **D**, The linear correlation between the expression level of MTA1 and LUCAT1 in cervical cancer tissues. The results represent the average of three independent experiments. Data are presented as the mean \pm standard error of the mean. $p < 0.05$.

the expression of tumor suppressor and leads to the formation and invasion of esophageal squamous cell carcinoma by regulating the stability of EMT1¹³. In addition, upregulation of lncRNA LUCAT1 is significantly related to malignant stage of clear cell renal cell carcinoma and predicts the poor prognosis of patients with ccRCC. In this research, we figured out that the expression of LUCAT1 was remarkably upregulated in both human cancer samples and cells. Besides, the clear relationship was observed between patients' prognosis and expression level of LUCAT1. Furthermore, after LUCAT1 was overexpressed, the proliferation, invasion and migration of cervical cancer cell were promoted. The results above indicated that LUCAT1 promoted tumorigenesis of cervical cancer and might act as an oncogene. Metastasis-associated protein 1 (MTA1), as an essential component of

the deacetylase (NuRD) complex and nucleosome remodeling, has been revealed to be a new factor that promotes the progression of epithelial-to-mesenchymal transition (EMT)¹⁵. For instance, through AKT/GSK3 β / β -catenin signaling, MTA1 promotes cell EMT and metastasis in non-small-cell lung cancer¹⁶. Increased levels of MTA1 promote cell invasion and metastasis in human hepatocellular carcinoma by regulating ErbB2¹⁷. Through repression of MTA1 expression, miR-183 could inhibit the EMT and progression of human pancreatic cancer¹⁸. In the present study, MTA1 expression could be upregulated after overexpression of LUCAT1. Moreover, MTA1 expression in cervical cancer samples was positively related to LUCAT1 expression. All the results above suggest that LUCAT1 might promote tumorigenesis of cervical cancer *via* upregulating MTA1.

Conclusions

We showed that LUCAT1 was remarkably up-regulated and was negatively related to overall survival time of patients with cervical cancer. Besides, LUCAT1 could enhance cell proliferation, invasion and migration in cervical cancer cells through upregulating MTA1. These findings suggest that LUCAT1 may contribute to therapy for cervical cancer as a candidate target.

Conflict of Interests

The authors declared no conflict of interest.

References

- DI J, RUTHERFORD S, CHU C. Review of the cervical cancer burden and population-based cervical cancer screening in China. *Asian Pac J Cancer Prev* 2015; 16: 7401-7407.
- SMALL WJ, BACON MA, BAJAJ A, CHUANG LT, FISHER BJ, HARKENRIDER MM, JHINGRAN A, KITCHENER HC, MILESHKIN LR, VISWANATHAN AN, GAFFNEY DK. Cervical cancer: a global health crisis. *Cancer* 2017; 128: 2404-2412.
- SONG W, MEI JZ, ZHANG M. Long noncoding RNA PlncRNA-1 promotes colorectal cancer cell progression by regulating the PI3K/Akt signaling pathway. *Oncol Res* 2018; 26: 261-268.
- PEI X, WANG X, LI H. LncRNA-p21 regulates the differentiation of Treg cells and affects the immune escape of breast cancer by regulating miR-448/IDO. *Int J Biochem Biomol* 2017; 118: 24-30.
- WANG Y, ZHANG X, MENG Z, LIU S, LIU S, LIU X, WU T, TAO X, LIU X, LI X, CHENG B. LncRNA-p23154 promotes the invasion and metastasis potential of human nasopharyngeal carcinoma by regulating p21-miR-21 and glycolysis. *Cancer Lett* 2018; 434: 172-183.
- BAI J, WANG RF, SHANG Y, LI S, YU GD, SUN C. Upregulation of long noncoding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma. *World J Gastroenterol* 2018; 17: 5328-5335.
- ZHANG RH, HAN J, ZHANG XQ, NIAN GX, WU MX, LIU Z, ZHANG Y, SUN ZG. Independent prognostic factor: low-expressed LncRNA ZNF667-51 for cervical cancer and inhibitory function on the proliferation of cervical cancer. *Eur Rev Med Pharmacol Sci* 2017; 21: 5353-5360.
- HUANG HW, XIE H, MA X, ZHAO F, GAO Y. Upregulation of LncRNA PANDAR predicts poor prognosis and promotes cell proliferation in cervical cancer. *Eur Rev Med Pharmacol Sci* 2017; 21: 4529-4535.
- MENG Y, LI Q, LI L, MA R. The long noncoding RNA CRNDE promotes cervical cancer cell growth and metastasis. *Biol Chem* 2017; 399: 93-100.
- ZHANG J, YAO T, WANG Y, YU J, LIU J, LIU Z. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating p21. *Cancer* 2016; 17: 104-113.
- THAI P, STATT S, CHEN Y, LIANG E, CAMPBELL C, WANG X. Characterization of a novel long noncoding RNA, SCAL1, induced by cigarette smoke and upregulated in lung cancer cell lines. *Mol Cell Biochem* 2013; 49: 209-211.
- SUN Y, LIU Q, HAN L, LIU XY, WANG W, WANG G. Long non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expression. *Oncotarget* 2017; 8: 28297-28311.
- YOON JH, YOU BH, PARK CH, KIM YJ, NAM JW, LEE SK. The long noncoding RNA LUCAT1 promotes tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in esophageal squamous cell carcinoma. *Cancer Lett* 2018; 417: 10-17.
- ZHENG Z, ZHAO F, ZHU D, HAN J, CHEN H, CAI Y, LIU J, LIU Z, XIE W. Long non-coding RNA LUCAT1 promotes proliferation and invasion in clear cell renal cell carcinoma through AKT/GSK-3beta signaling pathway. *Cell Physiol Biochem* 2018; 48: 891-904.
- DHAR S, KUMAR A, ZHANG L, RIMANDO AM, LAGE JM, LEWIN JR, ATFI A, ZHANG X, LEVENSON AS. Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer. *Oncotarget* 2016; 7: 18469-18484.
- MA K, FAN Y, DONG X, DONG D, GUO Y, WEI X, NING J, GENG Q, WANG C, HU Y, LI M, NIU W, LI E, WU Y. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer. *Oncotarget* 2017; 8: 38825-38840.
- DENG L, TANG J, YANG H, CHENG C, LU S, JIANG R, SUN B. MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway. *Oncogene* 2017; 36: 3976-3985.
- LIN X, ZHENG L, SONG H, XIAO J, PAN B, CHEN H, JIN X, YU H. Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targeting MTA1. *Exp Mol Pathol* 2017; 102: 522-532.